Annual report pursuant to Section 13 and 15(d)

Segments (Details)

v2.4.0.8
Segments (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Segment Reporting Information [Line Items]                      
Product revenues                 $ 68,161 $ 45,295 $ 27,844
Revenue from services                 11,658 1,749 135
Revenue from transfer of intellectual property                 16,711 0 0
Operating (loss) income         (1,039) (9,646) (10,244) (8,611) (79,632) (37,269) (23,189)
Depreciation and amortization                 15,216 10,160 3,830
Gain (Loss) on Investments                 (11,456) (2,062) (1,589)
Total revenues 20,692 20,641 23,821 31,376 16,261 11,795 10,211 8,777 96,530 47,044 27,979
Assets 1,391,516 [1]       289,830 [1]       1,391,516 [1] 289,830 [1]  
Goodwill 226,373 [1]       80,450 [1]       226,373 [1] 80,450 [1] 39,815
U.S. [Member]
                     
Segment Reporting Information [Line Items]                      
Total revenues                 28,369 1,749 135
Chile [Member]
                     
Segment Reporting Information [Line Items]                      
Total revenues                 31,650 26,514 21,466
Spain [Member]
                     
Segment Reporting Information [Line Items]                      
Total revenues                 18,800 6,124 0
Israel [Member]
                     
Segment Reporting Information [Line Items]                      
Total revenues                 13,252 7,655 0
Mexico [Member]
                     
Segment Reporting Information [Line Items]                      
Total revenues                 4,459 5,002 6,378
Corporate, Non-Segment [Member]
                     
Segment Reporting Information [Line Items]                      
Product revenues                 0 0 0
Revenue from services                 825 1,354 135
Revenue from transfer of intellectual property                 0 0 0
Operating (loss) income                 (24,473) (15,628) (15,537)
Depreciation and amortization                 149 179 170
Gain (Loss) on Investments                 0 0 0
Assets 209,539       35,109       209,539 35,109  
Goodwill                          
Segment Reconciling Items [Member]
                     
Segment Reporting Information [Line Items]                      
Operating (loss) income                 (3,151) (585) 0
Pharmaceutical [Member] | Chile [Member]
                     
Segment Reporting Information [Line Items]                      
Goodwill 6,102       6,697       6,102 6,697 5,282
Pharmaceutical [Member] | Mexico [Member]
                     
Segment Reporting Information [Line Items]                      
Goodwill 113       114       113 114 106
Pharmaceutical [Member] | Operating Segments [Member]
                     
Segment Reporting Information [Line Items]                      
Product revenues                 68,161 45,295 27,844
Revenue from services                 0 0 0
Revenue from transfer of intellectual property                 15,160 0 0
Operating (loss) income                 (29,809) (6,797) (3,668)
Depreciation and amortization                 8,234 6,367 2,804
Gain (Loss) on Investments                 (11,456) (2,062) (1,589)
Assets 1,065,033       142,299       1,065,033 142,299  
Goodwill 175,408       32,844       175,408 32,844  
Diagnostics [Member] | Operating Segments [Member]
                     
Segment Reporting Information [Line Items]                      
Product revenues                 0 0 0
Revenue from services                 10,833 395 0
Revenue from transfer of intellectual property                 1,551 0 0
Operating (loss) income                 (22,199) (14,259) (3,984)
Depreciation and amortization                 6,833 3,614 856
Gain (Loss) on Investments                 0 0 0
Assets 116,944       112,422       116,944 112,422  
Goodwill $ 50,965       $ 47,606       $ 50,965 $ 47,606  
[1] As of December 31, 2013 and 2012, total assets include $6.7 million and $5.6 million, respectively, and total liabilities include $10.4 million and $5.5 million, respectively related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and the holders of SciVac’s consolidated liabilities have no recourse against us. Refer to Note 3.